Homepage Top Section1

Niraparib delivered the desired result when given as monotherapy in the patient population, irrespective of biomarker status. The results of the PRIMA trial were presented at the 2019

The regulator has expanded the use of Dysport for injection to treat upper limb spasticity in children two years of age and older, excluding spasticity caused by cerebral

As per the agreement terms, Pfizer will tap into the de-identified, real-world datasets and analytical expertise from Flatiron Health to chalk out development strategies and activities for various

The mid-stage trial met the primary endpoint by recording a statistically significant improvement from baseline in motor symptoms in patients treated with tavapadon in comparison with those in

The partnership will see compounds from the retinal disease pipeline portfolio of Boehringer Ingelheim combined with the intravitreal (IVT) drug delivery technologies of Inflammasome. Inflammasome’s technology will be

The status was provided based on data from the phase II NOBILITY study in adult patients with proliferative lupus nephritis. Gazyva, in combination with standard of care (mycophenolate

Keytruda is Merck’s anti-PD-1 therapy, while Lenvima is the orally available kinase inhibitor discovered by Eisai. Keytruda plus Lenvima has been approved for the treatment of patients with

The Allergenic Products Advisory Committee (APAC) voted seven to two that the efficacy data and eight to one that the safety data, along with other safeguards, are enough

Nucala is claimed to be the only targeted biologic to secure approval for the condition in the six to 11-year age group in the US. The FDA approval